| Indicators of prognosis in node-negative breast cancer H Sigurdsson, B Baldetorp, Å Borg, M Dalberg, M Fernö, D Killander, ... New England Journal of Medicine 322 (15), 1045-1053, 1990 | 423 | 1990 |
| ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer Å Borg, B Baldetorp, M Fernö, D Killander, H Olsson, S Ryden, ... Cancer letters 81 (2), 137-144, 1994 | 360 | 1994 |
| ERBB2 amplification in breast cancer with a high rate of proliferation. A Borg, B Baldetorp, M Fernö, D Killander, H Olsson, H Sigurdsson Oncogene 6 (1), 137-143, 1991 | 273 | 1991 |
| Soft tissue leiomyosarcoma. A population‐based epidemiologic and prognostic study of 48 patients, including cellular DNA content P Gustafson, A Rydholm, H Willén, M Åkerman, B Baldetorp, M Fernö Cancer 70 (1), 114-119, 1992 | 233 | 1992 |
| Impedance spectra of tumour tissue in comparison with normal tissue; a possible clinical application for electrical impedance tomography B Blad, B Baldetorp Physiological measurement 17 (4A), A105, 1996 | 187 | 1996 |
| Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization K Rennstam, M Ahlstedt-Soini, B Baldetorp, PO Bendahl, A Borg, R Karhu, ... Cancer research 63 (24), 8861-8868, 2003 | 180 | 2003 |
| Chromosome aberrations in 35 primary ovarian carcinomas T Pejovic, S Heim, F Mitelman, N Mandahl, UM Flodérus, S Furgyik, ... Genes, Chromosomes and Cancer 4 (1), 58-68, 1992 | 168 | 1992 |
| Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast … P Rudolph, H Olsson, G Bonatz, V Ratjen, H Bolte, B Baldetorp, M Fernö, ... The Journal of pathology 187 (2), 207-216, 1999 | 163 | 1999 |
| Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma K Harbst, M Lauss, H Cirenajwis, K Isaksson, F Rosengren, T Törngren, ... Cancer research 76 (16), 4765-4774, 2016 | 129 | 2016 |
| Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. TA Alvegard, NO Berg, B Baldetorp, M Fernö, D Killander, J Ranstam, ... Journal of Clinical Oncology 8 (3), 538-547, 1990 | 121 | 1990 |
| Expression of cyclins E, A, and B, and prognosis in lymph node‐negative breast cancer H Kühling, P Alm, H Olsson, M Fernö, B Baldetorp, R Parwaresch, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2003 | 110 | 2003 |
| Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm B Baldetorp, M Dalberg, U Holst, G Lindgren Cytometry: The Journal of the International Society for Analytical Cytology …, 1989 | 108 | 1989 |
| Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node‐negative breast cancer P Rudolph, H Kühling, P Alm, M Fernö, B Baldetorp, H Olsson, ... International journal of cancer 105 (5), 674-680, 2003 | 107 | 2003 |
| UDP acts as a growth factor for vascular smooth muscle cells by activation of P2Y6 receptors M Hou, TK Harden, CM Kuhn, B Baldetorp, E Lazarowski, W Pendergast, ... American Journal of Physiology-Heart and Circulatory Physiology 282 (2 …, 2002 | 105 | 2002 |
| Heterogenous mismatch-repair status in colorectal cancer P Joost, N Veurink, S Holck, L Klarskov, A Bojesen, M Harbo, B Baldetorp, ... Diagnostic pathology 9, 1-10, 2014 | 103 | 2014 |
| Cytogenetic findings in 33 osteosarcomas F Mertens, N Mandahl, C Örndal, B Baldetorp, HCF Bauer, A Rydholm, ... International journal of cancer 55 (1), 44-50, 1993 | 102 | 1993 |
| Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer P Rudolph, P Alm, HJ Heidebrecht, H Bolte, V Ratjen, B Baldetorp, ... Journal of the National Cancer Institute 91 (3), 271-278, 1999 | 100 | 1999 |
| Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program H Svedberg, K Chylicki, B Baldetorp, F J Rauscher, U Gullberg Oncogene 16 (7), 925-932, 1998 | 96 | 1998 |
| c‐myc amplification is an independent prognostic factor in postmenopausal breast cancer Å Borg, B Baldetorp, M Fernö, H Olsson, H Sigurdsson International journal of cancer 51 (5), 687-691, 1992 | 84 | 1992 |
| Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene MM Tanner, RA Karhu, NN Nupponen, Å Borg, B Baldetorp, T Pejovic, ... The American journal of pathology 153 (1), 191-199, 1998 | 78 | 1998 |
